1. Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial
- Author
-
van der Hout, A. (A.), Jansen, F. (Femke), van Uden-Kraan, C.F. (Cornelia F.), Coupé, V.M.H. (Veerle), Holtmaat, K. (K.), Nieuwenhuijzen, G.A.P. (Gerard), Hardillo, J.A.U. (José), de Jong, R.J.B. (R. J. Baatenburg), Tiren-Verbeet, N.L. (N. L.), Sommeijer, D.W. (D. W.), de Heer, K. (K.), Schaar, C.G. (C. G.), Sedee, R.J.E. (R. J.E.), Bosscha, K. (Koop), Brekel, M.W.M. (Michiel W.) van den, Petersen, J.F. (J. F.), Westerman, M. (Matthijs), Honings, J. (Jimmie), Takes, R.P. (Robert), Houtenbos, I. (I.), Broek, W. (Wim) van den, Bree, R. (Remco) de, Jansen, P. (P.), Eerenstein, S.E.J. (Simone), Leemans, C.R. (René), Zijlstra, J.M. (Josée), Cuijpers, P. (Pim), Poll-Franse, L.V. (Lonneke) van de, Verdonck-De Leeuw, I.M. (Irma), van der Hout, A. (A.), Jansen, F. (Femke), van Uden-Kraan, C.F. (Cornelia F.), Coupé, V.M.H. (Veerle), Holtmaat, K. (K.), Nieuwenhuijzen, G.A.P. (Gerard), Hardillo, J.A.U. (José), de Jong, R.J.B. (R. J. Baatenburg), Tiren-Verbeet, N.L. (N. L.), Sommeijer, D.W. (D. W.), de Heer, K. (K.), Schaar, C.G. (C. G.), Sedee, R.J.E. (R. J.E.), Bosscha, K. (Koop), Brekel, M.W.M. (Michiel W.) van den, Petersen, J.F. (J. F.), Westerman, M. (Matthijs), Honings, J. (Jimmie), Takes, R.P. (Robert), Houtenbos, I. (I.), Broek, W. (Wim) van den, Bree, R. (Remco) de, Jansen, P. (P.), Eerenstein, S.E.J. (Simone), Leemans, C.R. (René), Zijlstra, J.M. (Josée), Cuijpers, P. (Pim), Poll-Franse, L.V. (Lonneke) van de, and Verdonck-De Leeuw, I.M. (Irma)
- Abstract
Purpose: The eHealth self-management application ‘Oncokompas’ was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and
- Published
- 2020
- Full Text
- View/download PDF